• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

scPharmaceuticals

Monday, June 03, 2024
CP
Cardiovascular
Founded in 2013, scPharmaceuticals Inc. is commercializing products that advance patient care and reduce healthcare costs by enabling subcutaneous administration at home for products that were previously limited to intravenous (IV) delivery in the hospital setting. FUROSCIX, a pH neutral, subcutaneous formulation of furosemide was FDA approved in October 2022 and launched in February 2023 for the treatment of congestion due to fluid overload in patients with heart failure (HF). A sNDA is pending to expand he indication to chronic kidney disease (CKD) with a PDUFA date of Q1-2025.
scPharmaceuticals
Company Website: https://www.scpharmaceuticals.com/
Lead Product in Development: FUROSCIX (furosemide injection) 80 mg/10mL for subcutaneous administration www.FUROSCIX.com
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Exchange

NASDAQ

Ticker

SCPH

Company HQ City

Burlington

Company HQ State

Massachusetts

Company HQ Country

United States

CEO/Top Company Official

John Tucker

Development Phase of Primary Product

Phase IV
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS